HCA
ADMA icon

Harbor Capital Advisors’s ADMA Biologics ADMA Stock Holding History

Harbor Capital Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4K Sell
514
-73
-12% -$665 ﹤0.01% 1147
2026
Q1 		$5K Sell
587
-66,242
-99% -$1.05M ﹤0.01% 1110
2025
Q4 		$1.22M Buy
66,829
+7,028
+12% +$118K 0.09% 289
2025
Q3 		$877K Buy
+59,801
New +$1.03M 0.07% 350

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Harbor Capital Advisors's ADMA Position: Q2 2026 in Review

Harbor Capital Advisors reduced its ADMA Biologics (ADMA) stake by 12% in Q2 2026, selling an estimated $665 and leaving 514 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1147.

Harbor Capital Advisors first reported a position in ADMA in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.22M in Q4 2025. 160 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Harbor Capital Advisors held 514 shares of ADMA Biologics worth $4K as of Q2 2026.
  • Harbor Capital Advisors sold 73 ADMA Biologics shares in Q2 2026, an estimated $665.
  • ADMA Biologics made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q2 2026, its #1147 holding.
  • Harbor Capital Advisors first reported a position in ADMA Biologics in Q3 2025 and has held it in 4 quarters since.
  • Harbor Capital Advisors's ADMA Biologics position peaked at $1.22M in Q4 2025.
  • 160 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.